Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 2/20 | 0.31 |
| ▸ | GUCY1B2 | O75343 | 3/20 | 0.31 |
| ▸ | GUCY1A2 | P33402 | 3/20 | 0.31 |
| ▸ | GUCY1A1 | Q02108 | 3/20 | 0.31 |
| ▸ | GUCY1B1 | Q02153 | 3/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20939870 | 0.73 | RBP4 (0.36) | HDAC2ATRRBP4 | |
| SCHEMBL20704269 | 0.72 | NR1H2 (0.41) | HTR6ATRDRD2DRD1 | |
| SCHEMBL20703947 | 0.72 | HSD17B3 (0.37) | HTR6GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL18376163 | 0.71 | GUCY1B2 (0.38) | HTR6GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL23066177 | 0.70 | C5AR1 (0.37) | HTR6GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL520464 | 0.69 | DRD1 (0.35) | DRD2DRD1 | |
| SCHEMBL20242603 | 0.69 | ATR (0.35) | HTR6ATRGUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL16961694 | 0.68 | ABHD6 (0.37) | — | |
| SCHEMBL18379228 | 0.68 | PDE1B (0.34) | HTR6 | |
| SCHEMBL18368367 | 0.68 | EGFR (0.36) | HTR6GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-30 | — | — | US | disclosed |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | US | disclosed |
| EP-3478673-B1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, NFKBIA, MAP3K15 | HDAC2 734/4885HTR6 4826/4885ATR 687/4885 |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | HDAC2 741/4885HTR6 4819/4885ATR 462/4885 |
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | HDAC2 734/4885HTR6 4826/4885ATR 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.